Stockscreener 앱 받기
0.2725
5.98%
-0.0166
Processa Pharmaceuticals Inc 주식(PCSA)의 최신 뉴스
Processa Pharmaceuticals Announces Public Offering Pricing - TipRanks
Processa inks licensing deal with Intact for gastroparesis drug By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) Sets Public Offering Price at $0 - GuruFocus
Processa Pharmaceuticals Signs Binding Term Sheet Granting - GlobeNewswire
Processa Pharmaceuticals (PCSA) Enters Licensing Agreement for G - GuruFocus
Processa Pharmaceuticals Prices of $7 Million Public Offering - citybiz
Processa inks licensing deal with Intact for gastroparesis drug - Investing.com
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering | PCSA Stock News - GuruFocus
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricin - GuruFocus
Processa Pharmaceuticals Prices $7 Million Public Offering - MarketScreener
Processa Pares Gains on Equity Offer News - MarketWatch
Processa Pharmaceuticals (PCSA) Announces Public Offering Pricing | PCSA Stock News - GuruFocus
Processa sells 28M shares at 25c in public offering - TipRanks
Processa sees 28M shares at 25c in public offering - TipRanks
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering - GlobeNewswire
Processa Pharmaceuticals Secures $7M Funding: Next-Generation Cancer Drug Trial Gets Green Light - Stock Titan
Processa Pharmaceuticals Announces Licensing Deal with Intact - TipRanks
Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal - Benzinga
Processa Pharmaceuticals Grants Intact Therapeutics Exclusive Option to License Gastroparesis Drug Candidate; Shares Rise - marketscreener.com
Processa Pharmaceuticals Skyrockets on Game-Changing Gastroparesis Deal - RagingBull
Processa Pharmaceuticals signs binding term sheet with Intact Therapeutics - TipRanks
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate - Yahoo Finance
Processa Pharmaceuticals (NASDAQ:PCSA) Trading Down 12.9% – Time to Sell? - Defense World
Navigating PCSA’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025 - GlobeNewswire
Processa Pharmaceuticals (PCSA) Prepares for Strategic Insights at BIO Convention 2025 | PCSA Stock News - GuruFocus
Processa to engage potential partners, investors at BIO International Convention - TipRanks
Processa Pharmaceuticals to Engage Potential Partners and Invest - GuruFocus
PCSA Stock Placement by H.C. Wainwright & Co. | PCSA Stock News - GuruFocus
Processa Pharmaceuticals to Showcase Next Generation Cancer Therapies at 2025 BIO International Convention - Nasdaq
Next-Gen Cancer Drug Developer Processa Pharma Eyes Strategic Partners at Major BIO Convention - Stock Titan
Processa Pharmaceuticals presents cancer drug advances at ASCO By Investing.com - Investing.com South Africa
Processa Pharmaceuticals (PCSA) Highlights Cancer Drug Advances at ASCO 2025 | PCSA Stock News - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication - GuruFocus
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting | PCSA Stock News - GuruFocus
Processa Pharmaceuticals presents cancer drug advances at ASCO - Investing.com Australia
Processa Pharmaceuticals Highlights Next Generation Cancer Therapies with Three Accepted Abstracts at 2025 ASCO Annual Meeting - Nasdaq
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting - GlobeNewswire
Latest Clinical Trial Data: Processa Presents 3 Cancer Treatment Breakthroughs at ASCO 2025 - Stock Titan
Processa Pharmaceuticals (NASDAQ:PCSA) Stock Price Down 1.5% – What’s Next? - Defense World
Processa Pharmaceuticals faces Nasdaq delisting risk over share price - MSN
Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 - Barchart.com
PCSAProcessa Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
There is no way Processa Pharmaceuticals Inc (PCSA) can keep these numbers up - Sete News
Processa Pharmaceuticals (PCSA) Expected to Announce Earnings on Friday - Defense World
Processa Pharmaceuticals Inc: Rising -91.68% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Taking a Closer Look At Processa Pharmaceuticals Inc (PCSA) Following Its Recent Trade - knoxdaily.com
Processa Pharmaceuticals Inc [PCSA] Shares Rise 8.43 % on Wednesday - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.65 - MSN
Processa Pharmaceuticals Inc (PCSA) can make a big difference with a little luck - Sete News
A Closer Look at Processa Pharmaceuticals Inc (PCSA) Stock Gains - investchronicle.com
Recent Insider Activity Suggests Potential Gains for Processa Pharmaceuticals Inc (PCSA) - knoxdaily.com
Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025 - GlobeNewswire
FDA Project Optimus: Processa Unveils New Approach for Rare Disease Treatment Success - Stock Titan
Data-Based Insights About Processa Pharmaceuticals Inc (PCSA) - stocksregister.com
Processa Pharmaceuticals stock hits 52-week low at $0.22 - Investing.com
PCSA Stock Sees Decline of Approximately -11.67% in Last Five Days - knoxdaily.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 - Investing.com
Processa Pharmaceuticals stock hits 52-week low at $0.36 By Investing.com - Investing.com India
Processa Pharmaceuticals (PCSA) to Release Quarterly Earnings on Friday - Defense World
1.54%
자본화:
|
볼륨(24시간):